News >

Ibrutinib Better Than Bendamustine for OS in CLL, Indirect Comparison Suggests

Jason Harris
Published: Friday, Apr 21, 2017

Blood cells
Results of a systematic literature search published online in Clinical Lymphoma, Myeloma & Leukemia showed that ibrutinib (Imbruvica) was associated with superior survival and fewer adverse events (AEs) compared with bendamustine (Treanda) in patients with chronic lymphocytic leukemia (CLL).

She added that researchers only observed 37 such AEs among 135 patients in the ibrutinib group. The researchers concluded that, based on this analysis, ibrutinib was a safer option than bendamustine overall, but noted that there were 6 incidents of severe bleeding in the ibrutinib group. There were no such incidents with bendamustine.
Andrasiak I, Rybka J, Knopinska-Posluszny W, Wrobel T. Efficacy and safety of bendamustine and ibrutinib in previously untreated patients with chronic lymphocytic leukemia–indirect comparison [published online March 7, 2017]. Clin Lymphoma Myeloma Leuk. doi: 10.1016/j.clml.2017.02.026.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: Advancing the Treatment of Bladder Cancers Using Evidence-Based Immuno-Oncology StrategiesJul 30, 20191.0
Medical Crossfire®: Where Are We Headed in the Treatment of Triple-Negative Breast Cancer?Jul 31, 20191.5
Publication Bottom Border
Border Publication